OptiBiotix Health’s Stephen O’Hara discusses the key points from their half-year report in this exclusive interview with DirectorsTalk
Hybridan’s Derren Nathan discusses Optibiotix Health PLC in this exclusive interview with DirectorsTalk
Optibiotix Health Plc (LON:OPTI) CEO Stephen O’Hara talks to DirectorsTalk about the release of it’s 6 month interim’s. Stephen talks about the IP, scientific, and commercial aspects of the results.
Optibiotix Health Plc (LON:OPTI) is the topic of conversation with Hybridan researcher and corporate broker Nathan Derren. The company has made great progress since its IPO and Nathan explains what
Stephen O’Hara, CEO of OptiBiotix LON:OPTI commented: “OptiBiotix has made significant progress in the last six months advancing our development programmes, building our IP portfolio, and signing commercial agreements with
According to a report in the Guardian medical experts have been criticising the governments tactics on tackling childhood obesity, stating that not only is it weak and embarrassing but they
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that GoFigure(R) meal replacement shakes and natural snack bars products
Stephen O’Hara, CEO of OptiBiotix PLC (LON:OPTI), commented: “Luis’s scientific and commercial experience in the microbiome space across food, biotech, and pharma provides additional breadth and capability to help capitalise on
Researchers in Germany have just discovered an antibiotic that is produced by bacteria found in our noses and is able to kill MRSA. This comes from an article posted on
The patent filing announced today highlight’s the multiple product opportunities that are ahead for OptiBiotix’s Lactobacillus plantarum cholesterol reducing strain. Having demonstrated efficacy as a single agent in a human
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
